What type of study is this?

This is a Experimental Study study.

Type I Rhodamine-Sensitized Iridium(III) Complex Photosensitizers Activate Pyroptosis for Hypoxic Photodynamic Immunotherapy

View Full Paper

Ask AI

Bookmark

Authors

Synthesized type I photosensitizers activate pyroptosis in tumors, highlighting potential in hypoxic photodynamic immunotherapy.

Type I photosensitizers induce pyroptosis in CT26 cells, leading to tumor ablation and a robust immune response.
Ir3 demonstrates an IC50 of 0.46 μM under hypoxia, significantly enhancing superoxide radical production.
Synthesis utilized a donor-acceptor strategy in cyclometalated Ir(III) complexes to improve phototoxicity substantially.
Findings imply a new pathway for designing hypoxia-tolerant photosensitizers for effective cancer treatment.

Shi et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

View Full Paper

Ask AI

Bookmark

Authors

Synthesized type I photosensitizers activate pyroptosis in tumors, highlighting potential in hypoxic photodynamic immunotherapy.

Type I photosensitizers induce pyroptosis in CT26 cells, leading to tumor ablation and a robust immune response.
Ir3 demonstrates an IC50 of 0.46 μM under hypoxia, significantly enhancing superoxide radical production.
Synthesis utilized a donor-acceptor strategy in cyclometalated Ir(III) complexes to improve phototoxicity substantially.
Findings imply a new pathway for designing hypoxia-tolerant photosensitizers for effective cancer treatment.

Shi et al. (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark